JAK-话题@MedSci

#JAK#

115篇内容 | 2657人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738010, encodeId=726a1e38010d5, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, objectType=article, longId=177980, objectId=fe551e798093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe551e798093, replyNumber=0, likeNumber=95, createdTime=2019-12-14, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe551e798093, moduleTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe551e798093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738034, encodeId=99fe1e380344b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=NEJM：Jakavi（ruxolitinib）治疗急性移植物抗宿主病，优于现有更佳疗法, objectType=article, longId=192864, objectId=1334192864b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1334192864b9, replyNumber=0, likeNumber=93, createdTime=2020-05-13, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1334192864b9, moduleTitle=NEJM：Jakavi（ruxolitinib）治疗急性移植物抗宿主病，优于现有更佳疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1334192864b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738016, encodeId=f4351e380165e, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：JAK2ex13Del驱动致癌转化，与慢性嗜酸性白血病和真性红细胞增多症相关, objectType=article, longId=181320, objectId=a75718132063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a75718132063, replyNumber=0, likeNumber=79, createdTime=2019-11-19, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a75718132063, moduleTitle=Blood：JAK2ex13Del驱动致癌转化，与慢性嗜酸性白血病和真性红细胞增多症相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a75718132063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738023, encodeId=37601e380236f, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Gastroenterology：JAK抑制剂不良事件风险评估, objectType=article, longId=186271, objectId=99061862e142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99061862e142, replyNumber=0, likeNumber=106, createdTime=2020-10-30, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99061862e142, moduleTitle=Gastroenterology：JAK抑制剂不良事件风险评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99061862e142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738019, encodeId=09d11e380194f, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, objectType=article, longId=185034, objectId=d32d1850343b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d32d1850343b, replyNumber=0, likeNumber=75, createdTime=2020-07-16, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d32d1850343b, moduleTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d32d1850343b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738022, encodeId=66cd1e3802242, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, objectType=article, longId=185935, objectId=6a1818593535, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1818593535, replyNumber=0, likeNumber=74, createdTime=2020-07-10, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1818593535, moduleTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1818593535)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738012, encodeId=bc4b1e3801256, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=68, createdTime=2019-09-25, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738008, encodeId=29d41e380081a, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点, objectType=article, longId=174843, objectId=33b11e4843cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33b11e4843cb, replyNumber=0, likeNumber=81, createdTime=2019-08-19, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33b11e4843cb, moduleTitle=Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33b11e4843cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738005, encodeId=b9391e380058b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Am J Transl Res：MiR-125a-3p通过靶向Smad4和Jak1负调节人脂肪来源的间充质干细胞的成骨细胞分化, objectType=article, longId=166816, objectId=06ba16681606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06ba16681606, replyNumber=0, likeNumber=104, createdTime=2019-12-08, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06ba16681606, moduleTitle=Am J Transl Res：MiR-125a-3p通过靶向Smad4和Jak1负调节人脂肪来源的间充质干细胞的成骨细胞分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06ba16681606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738009, encodeId=d2441e38009db, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, objectType=article, longId=177845, objectId=6bec1e7845da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bec1e7845da, replyNumber=0, likeNumber=60, createdTime=2020-03-16, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bec1e7845da, moduleTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bec1e7845da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738015, encodeId=c0191e38015ad, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, objectType=article, longId=180178, objectId=8f301801e8b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f301801e8b0, replyNumber=0, likeNumber=66, createdTime=2019-11-21, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f301801e8b0, moduleTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f301801e8b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738004, encodeId=de931e3800427, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=移植物抗宿主病治疗的新契机：FDA批准Jakafi用于类固醇难治性急性GVHD, objectType=article, longId=166799, objectId=12a0166e99b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12a0166e99b9, replyNumber=0, likeNumber=73, createdTime=2020-03-27, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12a0166e99b9, moduleTitle=移植物抗宿主病治疗的新契机：FDA批准Jakafi用于类固醇难治性急性GVHD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12a0166e99b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738003, encodeId=e9101e380035b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, objectType=article, longId=166254, objectId=0b72166254e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b72166254e3, replyNumber=0, likeNumber=68, createdTime=2020-01-08, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b72166254e3, moduleTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b72166254e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738000, encodeId=50a01e380002e, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：自分泌LTA信号驱动霍奇金淋巴瘤的NF-κB和JAK-STAT活性以及髓系基因的表达, objectType=article, longId=159619, objectId=f98615961934, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f98615961934, replyNumber=0, likeNumber=105, createdTime=2019-12-11, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f98615961934, moduleTitle=Blood：自分泌LTA信号驱动霍奇金淋巴瘤的NF-κB和JAK-STAT活性以及髓系基因的表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f98615961934)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738001, encodeId=a11c1e38001d4, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=由于肺栓塞风险，辉瑞调整了JAK通路抑制剂托法替尼治疗类风湿的给药剂量, objectType=article, longId=160825, objectId=984c1608252d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=984c1608252d, replyNumber=0, likeNumber=70, createdTime=2019-10-14, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=984c1608252d, moduleTitle=由于肺栓塞风险，辉瑞调整了JAK通路抑制剂托法替尼治疗类风湿的给药剂量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=984c1608252d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738013, encodeId=f8fd1e38013dd, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：Suz12失活与JAK3突变信号协同促进T-ALL进展, objectType=article, longId=179092, objectId=acf41e90921f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acf41e90921f, replyNumber=0, likeNumber=78, createdTime=2019-09-15, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acf41e90921f, moduleTitle=Blood：Suz12失活与JAK3突变信号协同促进T-ALL进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acf41e90921f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738002, encodeId=44d71e380028f, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, objectType=article, longId=161781, objectId=2f85161e81f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f85161e81f8, replyNumber=0, likeNumber=67, createdTime=2019-12-02, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f85161e81f8, moduleTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f85161e81f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738007, encodeId=ee751e380077b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：JAK2 V617F和CALR突变的人群发生率和表现, objectType=article, longId=170111, objectId=2f1f1e01113a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f1f1e01113a, replyNumber=0, likeNumber=122, createdTime=2019-07-28, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f1f1e01113a, moduleTitle=Blood：JAK2 V617F和CALR突变的人群发生率和表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f1f1e01113a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737995, encodeId=1f2a1e37995fc, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定, objectType=article, longId=149700, objectId=ed23149e009d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed23149e009d, replyNumber=0, likeNumber=70, createdTime=2018-10-08, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed23149e009d, moduleTitle=Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed23149e009d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738006, encodeId=d1801e3800648, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, objectType=article, longId=167491, objectId=1e2a16e491c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2a16e491c8, replyNumber=0, likeNumber=75, createdTime=2020-02-17, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2a16e491c8, moduleTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e2a16e491c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JAK

2020-05-29

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化

2019-12-14

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

NEJM：Jakavi（ruxolitinib）治疗急性移植物抗宿主病，优于现有更佳疗法

2020-05-13

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：JAK2ex13Del驱动致癌转化，与慢性嗜酸性白血病和真性红细胞增多症相关

2019-11-19

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Gastroenterology：JAK抑制剂不良事件风险评估

2020-10-30

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎

2020-07-16

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎

2020-07-10

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点

2019-09-25

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点

2019-08-19

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Am J Transl Res：MiR-125a-3p通过靶向Smad4和Jak1负调节人脂肪来源的间充质干细胞的成骨细胞分化

2019-12-08

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎

2020-03-16

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功

2019-11-21

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

移植物抗宿主病治疗的新契机：FDA批准Jakafi用于类固醇难治性急性GVHD

2020-03-27

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果

2020-01-08

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：自分泌LTA信号驱动霍奇金淋巴瘤的NF-κB和JAK-STAT活性以及髓系基因的表达

2019-12-11

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

由于肺栓塞风险，辉瑞调整了JAK通路抑制剂托法替尼治疗类风湿的给药剂量

2019-10-14

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：Suz12失活与JAK3突变信号协同促进T-ALL进展

2019-09-15

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化

2019-12-02

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：JAK2 V617F和CALR突变的人群发生率和表现

2019-07-28

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定

2018-10-08

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果

2020-02-17

科室
- - 订阅+
  - 更多科室
工具
服务